关注
Najah Albadari
Najah Albadari
在 uoh.edu.sa 的电子邮件经过验证
标题
引用次数
引用次数
年份
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
N Albadari, S Deng, W Li
Expert opinion on drug discovery 14 (7), 667-682, 2019
2702019
Structure–activity relationship study of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiproliferative properties
H Chen, S Deng, Y Wang, N Albadari, G Kumar, D Ma, W Li, SW White, ...
Journal of Medicinal Chemistry 63 (2), 827-846, 2019
402019
Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents
H Chen, S Deng, N Albadari, MK Yun, S Zhang, Y Li, D Ma, DN Parke, ...
Journal of medicinal chemistry 64 (16), 12049-12074, 2021
362021
Survivin small molecules inhibitors: recent advances and challenges
N Albadari, W Li
Molecules 28 (3), 1376, 2023
272023
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
W Wang, N Albadari, Y Du, JF Fowler, HT Sang, W Xian, F McKeon, W Li, ...
Pharmacological Reviews 76 (3), 414-453, 2024
52024
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold
N Albadari, S Deng, H Chen, G Zhao, J Yue, S Zhang, DD Miller, Z Wu, ...
European journal of medicinal chemistry 224, 113719, 2021
52021
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C
ZN Lei, N Albadari, QX Teng, H Rahman, JQ Wang, Z Wu, D Ma, ...
Drug Resistance Updates 73, 101065, 2024
22024
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
N Albadari, Y Xie, W Li
Frontiers in Pharmacology 14, 1340401, 2024
22024
MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
T Liu, L Gu, Z Wu, N Albadari, W Li, M Zhou
Frontiers in Oncology 12, 1058726, 2022
12022
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
W Wang, Y Du, S Datta, JF Fowler, HT Sang, NG Albadari, W Li, J Foster, ...
Genes & Diseases, 101156, 2023
2023
Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
N Albadari, Y Xie, T Liu, R Wang, L Gu, M Zhou, Z Wu, W Li
European Journal of Medicinal Chemistry 255, 115423, 2023
2023
Discovery of Inhibitors of Inhibitors of Apoptosis Proteins and Novel Tubulin Polymerization Inhibitors as Potential Anticancer Agents
NG Albadari
2023
Colchicine binding site agents as potent tubulin inhibitors suppressing triple negative breast cancer
S Deng, H Chen, R Krutilina, NG Albadari, TN Seagroves, DD Miller, W Li
Cancer Research 79 (13_Supplement), 4608-4608, 2019
2019
Discovery of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitor with potent antiproliferative properties
H Chen, S Deng, N Albadari, D Miller, W Li
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 257, 2019
2019
An Mdm2 Degrader Shows Potent Cytotoxicity to Mdm2-Overexpressing Acute Lymphoblastic Leukemia Cells with Minimal Toxicity to Normal Cells/Tissues
T Liu, L Gu, A Mui, Z Wu, N Albadari, M Zhou, W Li
Tissues, 0
系统目前无法执行此操作,请稍后再试。
文章 1–15